The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ipilimumab retreatment following induction therapy: The expanded access program (EAP) experience.
Kim Allyson Margolin
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Omid Hamid
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Jeffrey S. Weber
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Anna C. Pavlick
Honoraria - Bristol-Myers Squibb; Genentech
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U); Genentech (U); Merck (U); Novartis (U)
Research Funding - Bristol-Myers Squibb; Genentech; Merck; Novartis
Asim Amin
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Kelly Bennett
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Tracy Michener
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
David R. Minor
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb